Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

ClinicalTrials.gov ID: NCT03513016

Public ClinicalTrials.gov record NCT03513016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.

Study identification

NCT ID
NCT03513016
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Unity Biotechnology, Inc.
Industry
Enrollment
78 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
40 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 15, 2018
Primary completion
Mar 28, 2019
Completion
Apr 11, 2019
Last update posted
Apr 19, 2020

2018 – 2019

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
TriWest Research Associates El Cajon California 92020
BioSolutions Clinical Research Center La Mesa California 91942
Well Pharma Medical Research Miami Florida 33132
Center for Pharmaceutical Research Kansas City Missouri 64114
Clinical Research Consortium Las Vegas Nevada 89119
Altoona Center for Clinical Research Duncansville Pennsylvania 16635
Metroplex Clinical Research Center Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03513016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2020 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03513016 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →